Company: Merck & Co.
Job title: Global Director Medical Affairs, Oncology, Thoracic & Pan Tumor Biomarkers & Diagnostics, Oncology Global Medical Affairs
NY-ESO-1 TCR T-cell Therapy in Synovial Sarcoma 5:15 pm
• Letetresgene autoleucel (lete-cel; GSK3377794) is a T-cell receptor (TCR) T-cell therapy specific to the NY-ESO-1 peptide-displaying antigen, a highly immunogenic cancer/testis antigen expressed in synovial sarcoma, that promotes an anticancer immune response. • A Phase I study in patients with previously-treated advanced synovial sarcoma whose tumors express NY-ESO-1 protein indicated that lete-cel infusion was…Read more
day: Day One